Literature DB >> 2153040

The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium.

G Thamsborg1, T L Storm, E Brinch, R Sykulski, N Fogh-Andersen, S N Holmegaard, O H Sørensen.   

Abstract

To investigate the effect of low doses of intranasal salmon calcitonin on plasma cyclic AMP (cAMP) and serum ionized calcium, 40 healthy postmenopausal women were randomized to receive a single dose of either placebo or 50, 100, or 200 IU of salmon calcitonin as a nasal spray. Blood samples were collected throughout an 8-hour period. None of the doses could provoke detectable hypocalcemia, whereas 100 and 200 IU of salmon calcitonin were associated with an increase in plasma cAMP after 15 minutes. Measurable plasma levels of salmon calcitonin were demonstrated in all active treatment groups, and the calculated areas under the curves showed a dose-dependent increase.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2153040     DOI： 10.1007/bf02555817

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  9 in total

1.  Intranasal calcitonin and plasma calcium concentrations in normal subjects.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

2.  Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients.

Authors:  J Y Reginster; A Albert; P Franchimont
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

3.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

4.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

5.  Diurnal variation in cyclic A.M.P. in plasma.

Authors:  P Pujol-Amat; E Davi; J Martin-Comin; R Monfort
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

6.  Long-term calcitonin therapy in postmenopausal osteoporosis.

Authors:  H E Gruber; J L Ivey; D J Baylink; M Matthews; W B Nelp; K Sisom; C H Chesnut
Journal:  Metabolism       Date:  1984-04       Impact factor: 8.694

Review 7.  Calcitonin: physiology and pathophysiology.

Authors:  L A Austin; H Heath
Journal:  N Engl J Med       Date:  1981-01-29       Impact factor: 91.245

8.  Circadian rhythms of blood minerals in humans.

Authors:  M Markowitz; L Rotkin; J F Rosen
Journal:  Science       Date:  1981-08-07       Impact factor: 47.728

9.  Effects of parathyroid hormone and calcitonin on plasma and nephrogenous cyclic adenosine-3',5'-monophosphate in normal subjects and in pathological conditions.

Authors:  A Caniggia; C Gennari; F Lore; R Nuti; M Galli
Journal:  Eur J Clin Invest       Date:  1980-04       Impact factor: 4.686
  9 in total
  6 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

2.  Effect of different doses of nasal salmon calcitonin on bone mass.

Authors:  G Thamsborg; T L Storm; R Sykulski; E Brinch; H K Nielsen; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

3.  Acute effects of nasal salmon calcitonin on calcium and bone metabolism.

Authors:  G Thamsborg; S G Skousgaard; H Daugaard; S Schifter; G Kollerup; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

Review 4.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

5.  The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Authors:  W A Lee; R D Ennis; J P Longenecker; P Bengtsson
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

6.  Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.

Authors:  G Kollerup; A P Hermann; K Brixen; B E Lindblad; L Mosekilde; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.